BEAM * logo

Beam Therapeutics BMV:BEAM * Stock Report

Last Price

Mex$335.00

Market Cap

Mex$32.8b

7D

2.1%

1Y

n/a

Updated

16 May, 2025

Data

Company Financials +

Beam Therapeutics Inc.

BMV:BEAM * Stock Report

Market Cap: Mex$32.8b

BEAM * Stock Overview

A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. More details

BEAM * fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 38.82% per year

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Beam Therapeutics Inc. Competitors

Genomma Lab Internacional. de

BMV:LAB B

Mex$20.9b

Recursion Pharmaceuticals

NasdaqGS:RXRX

US$1.8b

Bavarian Nordic

CPSE:BAVA

DKK 12.7b

BioArctic

OM:BIOA B

SEK 15.5b

Price History & Performance

Summary of share price highs, lows and changes for Beam Therapeutics
Historical stock prices
Current Share PriceUS$335.00
52 Week HighUS$590.00
52 Week LowUS$310.00
Beta2.35
1 Month Change4.69%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-58.44%

Recent News & Updates

Recent updates

Shareholder Returns

BEAM *MX BiotechsMX Market
7D2.1%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how BEAM * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how BEAM * performed against the MX Market.

Price Volatility

Is BEAM *'s price volatile compared to industry and market?
BEAM * volatility
BEAM * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: BEAM *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine BEAM *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017393John Evansbeamtx.com

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies.

Beam Therapeutics Inc. Fundamentals Summary

How do Beam Therapeutics's earnings and revenue compare to its market cap?
BEAM * fundamental statistics
Market capMex$32.80b
Earnings (TTM)-Mex$7.55b
Revenue (TTM)Mex$1.24b

26.4x

P/S Ratio

-4.3x

P/E Ratio

Is BEAM * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BEAM * income statement (TTM)
RevenueUS$63.58m
Cost of RevenueUS$365.65m
Gross Profit-US$302.07m
Other ExpensesUS$85.27m
Earnings-US$387.34m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-3.97
Gross Margin-475.12%
Net Profit Margin-609.24%
Debt/Equity Ratio0%

How did BEAM * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 05:55
End of Day Share Price 2025/05/15 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Beam Therapeutics Inc. is covered by 23 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Konstantinos BiliourisBMO Capital Markets Equity Research
Alec StranahanBofA Global Research